Lipoprotein Testing denials in California external review
In the California DMHC record, independent physician reviewers decided 12 published external-review cases involving Lipoprotein Testingand overturned the plan’s denial in 0%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Conditions behind Lipoprotein Testing denials
| Category | Decisions | Overturned |
|---|---|---|
| Hyperlipidemia | 5 | 0% |
What the reviewers wrote
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for gene panel testing and/or the advanced lipoprotein testing. Lipoprotein(a) is a causal independent risk factor for atherosclerotic cardiovascular disease events. The risk of atherosclerotic cardiovascular disease events has been shown to increase linearly with lipoprotein(a) concentrations. The National Lipid Association (NLA) stated that lipoprotein(a) testing may be reasonable to refine atherosclerotic cardiovascular disease risk in adults with specific risk factors. Per the NLA, a personal history of premature atherosclerotic cardiovascular disease, primary severe hypercholesterolemia, or suspected familial hypercholesterolemia, or for patients with first-degree relatives with premature atherosclerotic cardiovascular disease.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested reimbursement for advanced lipoprotein testing, including lipoprotein (a). Advanced lipoprotein testing may provide additional risk stratification for atherosclerotic cardiovascular disease; however, current clinical guidelines do not recommend routine use in low risk individuals or in patients without established indications. Management decisions in most patients remain based on standard lipid panels and overall cardiovascular risk assessment, with treatment focused on established therapies such as statins.In this case, there is no documentation of high risk conditions such as established atherosclerotic cardiovascular disease, diabetes mellitus, or a strong family history that would support the need for advanced lipoprotein testing.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Lipoprotein Testing, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY